Bimatoprost

證據等級: L5

預測適應症: 10 個

Bimatoprost: From Glaucoma/Ocular Hypertension to Periodontal Malformation Syndrome

One-Sentence Summary

Bimatoprost is a synthetic prostamide F2α analogue originally approved for treating glaucoma and ocular hypertension (Lumigan®) and eyelash hypotrichosis (Latisse®), though it is not currently marketed in Canada or Taiwan. The TxGNN model predicts it may be effective for malformation syndrome with odontal and/or periodontal component, with 0 clinical trials and 20 publications retrieved — however, none of these publications directly examine bimatoprost in this condition. The prediction is driven by knowledge graph topology and lacks pharmacological support; current evidence is L5 only.

Quick Overview

Item	Content
Original Indication	Glaucoma / Ocular hypertension (globally approved; no Canada/Taiwan registration on record)
Predicted New Indication	Malformation syndrome with odontal and/or periodontal component
TxGNN Prediction Score	99.997%
Evidence Level	L5
Canada Market Status	Not marketed
Number of DINs	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the evidence pack. Based on published pharmacological literature, bimatoprost is a synthetic prostamide F2α analogue (FP prostaglandin receptor agonist). Its efficacy in reducing intraocular pressure is well established, and its FDA-approved use for eyelash hypotrichosis (Latisse®, 0.03% solution) reflects its ability to activate FP receptors in hair follicle dermal papilla cells, prolonging the anagen (growth) phase and enlarging follicle diameter.

The predicted indication — malformation syndrome with odontal and/or periodontal component — refers to conditions involving structural abnormalities of teeth and the surrounding periodontal tissues. Prostaglandins (particularly PGE2) are known mediators of periodontal inflammation and alveolar bone remodeling. However, bimatoprost specifically targets the FP receptor subtype; there is no established link between FP receptor agonism and the developmental/malformation pathways that drive odontal and periodontal malformation syndromes, which are typically genetic in origin.

Critically, all 20 publications retrieved are general periodontal disease literature (e.g., EFP clinical guidelines, subgingival microbial complex studies, gingival fibroblast biology) — none involve bimatoprost. The high TxGNN score most likely reflects knowledge graph topological proximity (bimatoprost → hair follicle → connective tissue → periodontal tissue) rather than a true pharmacological relationship. This prediction should be considered a graph noise artifact at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Twenty publications were retrieved; however, none examine bimatoprost in this indication. All papers are general periodontal disease research and are listed below for completeness.

PMID	Year	Type	Journal	Key Findings
35688447	2022	Clinical Practice Guideline	J Clin Periodontol	EFP S3-level CPG for Stage IV periodontitis treatment
22057194	2012	Review	Diabetologia	Bidirectional relationship between periodontitis and diabetes; ~3× increased susceptibility in diabetic patients
37435999	2023	Review	Periodontology 2000	Complications and treatment errors in regenerative periodontal surgery
35420698	2022	Cochrane Systematic Review	Cochrane Database Syst Rev	Periodontal treatment and glycaemic control in diabetes; subgingival instrumentation assessed
39233377	2024	Review	Periodontology 2000	Sleep disorders (especially OSA) as emerging risk factor for periodontal disease
36883660	2023	Review	J Dent Res	Gingival fibroblasts as sentinel innate immune cells in periodontitis pathogenesis
9495612	1998	Observational Study	J Clin Periodontol	Characterisation of microbial complexes in subgingival plaque (n=185)
12010523	2002	Review	J Clin Periodontol	Evidence-based assessment of scaling and root planing as gold standard for chronic periodontitis
38907216	2024	Review	J Nanobiotechnol	Biomaterial-mediated macrophage immunotherapy as a novel direction in periodontitis treatment
20599785	2010	Review	Biochem Pharmacol	Complement system overactivation contributing to immunopathology in periodontitis

⚠️ Important caveat: None of the 20 retrieved publications involve bimatoprost. This literature represents background periodontology research only. No direct evidence connecting bimatoprost to odontal/periodontal malformation syndrome was identified.

Canada Market Information

Bimatoprost is currently not marketed in Canada. No Drug Identification Numbers (DINs) are registered with Health Canada.

DIN	Product Name	Dosage Form	Approved Indication
—	No licensed products on record	—	—

Bimatoprost is marketed in other jurisdictions (e.g., Lumigan® for glaucoma and Latisse® for eyelash hypotrichosis in the USA), but Canada regulatory data was not found in the evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Detailed warnings, contraindications, and drug interaction data were not available in the current evidence pack. Safety data should be obtained from the Health Canada product monograph or the FDA-approved labelling (Lumigan®/Latisse®) before any further evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: This TxGNN prediction scores 99.997% but is supported by L5 evidence only — no clinical trials and no bimatoprost-specific literature for periodontal malformation syndrome. The mechanistic link between FP receptor agonism and odontal/periodontal malformation pathology is not established, and the repurposing rationale analysis identifies this as a probable knowledge graph topology artefact rather than a true pharmacological signal.

To proceed, the following is needed:

Confirm MOA data for bimatoprost (specifically: does FP receptor signalling play any role in periodontal ligament, cementum, or odontal development?)
Conduct a targeted literature search for prostaglandin FP receptor involvement in congenital odontal/periodontal malformation syndromes
Determine whether high TxGNN rank reflects a true biological signal or graph noise (e.g., compare with known FP receptor biology in craniofacial development)
Obtain Canada/Taiwan package insert and safety data before advancing to any Stage 1 assessment
Consider deprioritising this indication in favour of the alopecia indication (Rank 8), which has L2 evidence and an “Proceed with Guardrails” recommendation supported by multiple completed Phase 2 RCTs
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.